Completed PHASE1 INTERVENTIONAL 4-arm NCT02128022

Cardioprotective Effects of GLP-1 and Their Mechanisms

Investigation Into Cardioprotective Effect of Glucagon-like Peptide-1 and it's Mechanism of Action During Myocardial Ischaemia

Sponsor: Papworth Hospital NHS Foundation Trust

Conditions Angina Pectoris

Interventions GLP-1 (7-36) amide Glibenclamide

Updated 5 times since 2017 Last updated: Apr 8, 2016 Started: Jul 31, 2014 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02128022, this PHASE1 trial focuses on Angina Pectoris and remains completed. Sponsored by Papworth Hospital NHS Foundation Trust, it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Papworth Hospital NHS Foundation Trust

Data source: Papworth Hospital NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cambridge, United Kingdom